Abstract:Aging is the number one non-modifiable risk factor for cancer, including myeloid malignancies, such as Acute Myeloid leukemia (AML). Intrinsic changes within hematopoietic stem cells (HSC) with aging contribute to HSC dysfunction and may predispose to leukemia. We have previously shown that aged human HSC present a reduction of H3K27ac at active promoters and enhancers of genes associated with immune and cancer pathways. Concurrent with this epigenetic deregulation there is deregulation of immune-associated genes and downregulation of the bromodomain containing protein-9 (BRD9). This protein is a component of the non-canonical BAF (nc-BAF) chromatin remodeling complex, which binds to both active enhancers and promoters. Notably alteration of BRD9 has been shown to perturb immune and cancer associated pathways, with BRD9 regulating interferon-stimulated genes. However, little is known about the role of this protein in human hematopoiesis. Therefore, we hypothesize that chromatin remodeling due to loss of BRD9 with HSC aging leads to reduction of H3K27ac at active enhancers and promoters, contributing to HSC dysfunction. To investigate this, we treated human CD34+ hematopoietic stem and progenitor cells (HSPC) with dBRD9-A (100 nM) a chemical degrader of BRD9. Loss of BRD9 resulted in enhanced myeloid differentiation in vitro with a concurrent block in erythroid differentiation. Interestingly, amongst the myeloid populations upregulated with loss of BRD9 were monocytic myeloid derived suppressor cells (M-MDSC), immunosuppressive cells that are involved both in cancer pathogenesis and aging. Treatment with the BRD9 bromodomain specific inhibitor, I-BRD9 (1 μM), suggests that while the role of BRD9 in myeloid differentiation is largely bromodomain independent, the bromodomain may regulate erythroid differentiation. Similarly, loss of BRD9 leads to more myeloid biased colonies, suggesting that loss of BRD9 may recapitulate certain features of aged HSC. At the transcriptional level, RNA-seq revealed that loss of BRD9 resulted in few, but important differentially expressed genes, including downregulation of MPO, LIF, EPX, and GZMB (FDR < 0.05). However, gene set enrichment analysis showed that both bromodomain inhibition and loss of BRD9 resulted in downregulation of interferon and STAT3 associated genes, which are known BRD9 targets. Chromatin profiling of H3K27ac with CUT&RUN in young HSPC showed that with loss of BRD9, there is a reduction of H3K27ac at active enhancers that we had previously observed have loss of H3K27ac with human HSC aging (n=2). These active enhancers are associated with immune signaling and regulate hematopoietic transcription factors such as KLF6, RUNX1/2/3, and HIF1A. In conclusion, we have found that the chromatin remodeling protein BRD9 contributes to the reprogramming of age-associated enhancers and regulates human myeloid and erythroid differentiation in vitro, and that its loss may result in an expansion of M-MDSC, which has implications for age-related disorders such as immune dysfunction and cancer. Citation Format: Emmalee R. Adelman, Maria E. Figueroa. Determining the role of BRD9 in human hematopoietic stem cell aging. [abstract]. In: Proceedings of the AACR Special Conference: Cancer Epigenomics; 2022 Oct 6-8; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2022;82(23 Suppl_2) nr B010.

BRD9-mediated control of the TGF-β/Activin/Nodal pathway regulates self-renewal and differentiation of human embryonic stem cells and progression of cancer cells

BRD9 regulates normal human hematopoietic stem cell function and lineage differentiation

BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin state

Tumor suppressor bromodomain-containing protein 7 cooperates with Smads to promote transforming growth factor-β responses

BRD9-SMAD2/3 orchestrates stemness and tumorigenesis in pancreatic ductal adenocarcinoma

Smad7 Enables STAT3 Activation and Promotes Pluripotency Independent of TGF-β Signaling

Bromodomain-containing protein 9 promotes hepatocellular carcinoma progression via activating the Wnt/β-catenin signaling pathway

Abstract B010: Determining the role of BRD9 in human hematopoietic stem cell aging

Pan‐cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours

Bromodomain-containing protein 9 activates proliferation and epithelial-mesenchymal transition of colorectal cancer via the estrogen pathway in vivo and in vitro

BRD8 guards the pluripotent state by sensing and maintaining histone acetylation

Β-Catenin and Associated Proteins Regulate Lineage Differentiation in Ground State Mouse Embryonic Stem Cells

A Conserved Role of Shp2 in Regulation of Human and Mouse Es Cell Differentiation

Site-Specific Disruption of the Oct4/Sox2 Protein Interaction Reveals Coordinated Mesendodermal Differentiation and the Epithelial-Mesenchymal Transition

hnRNPLL controls pluripotency exit of embryonic stem cells by modulating alternative splicing of Tbx3 and Bptf

LncKdm2b Controls Self-Renewal of Embryonic Stem Cells Via Activating Expression of Transcription Factor Zbtb3.

An Embryonic Stem Cell Chromatin Remodeling Complex, Esbaf, is Essential for Embryonic Stem Cell Self-Renewal and Pluripotency

Smad2 Mediates Activin/Nodal Signaling in Mesendoderm Differentiation of Mouse Embryonic Stem Cells

Regulation of embryonic stem cell self-renewal and differentiation by TGF-β family signaling

LncRNA-Smad7 mediates cross-talk between Nodal/TGF-β and BMP signaling to regulate cell fate determination of pluripotent and multipotent cells

The Role of SMAD2/3 in Human Embryonic Stem Cells